Clinical Research Directory

Inclusion Criteria: 1. Male or female at least 18 years old; 2. diagnosed with AS according to the 1984 New York Modified Criteria; 3. Poor response after at least 2 NSAIDs (cumulative treatment ≥ 4 weeks), or contraindication or intolerance to NSAIDs therapy; 4. BASDAI score of ≥ 4 and total back pain VAS score of ≥ 4 at baseline; 5. Subjects who need to take NSAIDs (including COX-1 or COX-2 inhibitors) as established treatment for AS, and the NSAIDs should be on a stable dose for at least 2 weeks (inclusive) before screening and the dose is expected to be stable during the study; 6. Voluntary treatment with adalimumab and secukinumab; 7. Appropriate contraceptive measures for women of childbearing age; 8. without other rheumatic diseases. 9. Able to understand study requirements, provide written informed consent, and comply with trial protocol procedures (including required visits) Exclusion Criteria: 1. With unstable vital signs, coma, mental and cognitive impairment; 2. Patients with severe systemic diseases and other serious chronic diseases; 3. Pregnant or lactating patients; 4. History of malignant tumor in the past 5 years; 5. Positive test for the following infection markers: human immunodeficiency virus (HIV), hepatitis B, hepatitis C, syphilis antibody; 6. Patients with active or recurrent history of infection; With active tuberculosis or have a history of active tuberculosis in the past; 7. Moderate to severe heart failure (New York Heart Association grade 3-4); 8. Allergic to any of the components of adalimumab (HS016) or secukinumab; 9. Subjects who are participating in clinical research of other drugs; 10. In addition to the above, the investigator judged that there are other reasons that are not suitable for participating in this clinical study.